Overview

Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma

Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to investigate the efficacy and safety of sacituzumab govitecan in patients with advanced esophageal squamous cell carcinoma.
Phase:
PHASE2
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborator:
Gilead Sciences
Treatments:
sacituzumab govitecan